RJA
PFE icon

Ross\Johnson & Associates’s Pfizer PFE Stock Holding History

Ross\Johnson & Associates’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Buy
92
+9
+11% +$235 0.03% 70
2026
Q1 		$2.33K Sell
83
-5
-6% -$133 0.04% 66
2025
Q4 		$2.19K Buy
88
+2
+2% +$50 0.04% 70
2025
Q3 		$2.19K Hold
86
– – 0.04% 67
2025
Q2 		$2.08K Hold
86
– – 0.04% 65
2025
Q1 		$2.18K Buy
86
+6
+8% +$157 0.04% 159
2024
Q4 		$2.12K Buy
+80
New +$2.17K 0.05% 69

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ross\Johnson & Associates's PFE Position: Q2 2026 in Review

Ross\Johnson & Associates increased its Pfizer (PFE) stake by 11% in Q2 2026, buying an estimated $235 and bringing the position to 92 shares worth $2.21K. The position accounts for 0.03% of the portfolio, ranked #70.

Ross\Johnson & Associates first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.33K in Q1 2026. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Ross\Johnson & Associates held 92 shares of Pfizer worth $2.21K as of Q2 2026.
  • Ross\Johnson & Associates bought 9 Pfizer shares in Q2 2026, an estimated $235.
  • Pfizer made up 0.03% of Ross\Johnson & Associates's portfolio in Q2 2026, its #70 holding.
  • Ross\Johnson & Associates first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Ross\Johnson & Associates's Pfizer position peaked at $2.33K in Q1 2026.
  • 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.